Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.80 |
| ▸ | MAP2K4 | P45985 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | MAPKAPK3 | Q16644 | 4/20 | 0.44 |
| ▸ | MAPK6 | Q16659 | 4/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.44 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.44 |
| ▸ | CLK2 | P49760 | 7/20 | 0.43 |
| ▸ | CLK3 | P49761 | 7/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387406 | 0.90 | CSNK1D (0.82) | CSNK1DCLK2CLK3DYRK1AKDM4E | |
| SCHEMBL5378193 | 0.89 | CSNK1D (0.80) | CSNK1DMAPK1CLK2CLK3DYRK1A | |
| SCHEMBL5296238 | 0.89 | CSNK1D (1.00) | CSNK1DCLK2CLK3DYRK1AWNT1 | |
| SCHEMBL14564654 | 0.88 | CSNK1D (0.76) | CSNK1DCLK2CLK3DYRK1AALDH1A1 | |
| SCHEMBL5383771 | 0.88 | CSNK1D (0.98) | CSNK1DCLK2CLK3DYRK1AWNT1 | |
| SCHEMBL8437359 | 0.87 | CSNK1D (0.71) | CSNK1DCLK2CLK3DYRK1AWNT1 | |
| SCHEMBL17801058 | 0.86 | CSNK1D (0.76) | CSNK1DMAPK1CLK2CLK3DYRK1A | |
| SCHEMBL4079762 | 0.85 | CSNK1D (0.74) | CSNK1DMAPKAPK2CLK2CLK3DYRK1A | |
| SCHEMBL5379726 | 0.85 | CSNK1D (0.74) | CSNK1DCLK2CLK3DYRK1AALDH1A1 | |
| SCHEMBL5381505 | 0.85 | CSNK1D (0.70) | CSNK1DCLK2CLK3DYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9598669-B2 | Composition for collecting placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-20100291679-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | CELGENE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070190042-A1 | Composition for collecting and preserving placental stem cells and methods of using the composition | Celularity, Inc. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190042-A1 | Composition for collecting and preserving placental stem cells and methods of using the composition | PGF, ALPP, CPA1 | CSNK1D 3318/4885MAP2K4 4365/4885MAPK1 3959/4885 |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | MAP3K6, MAP3K1, MAPK1 | CSNK1D 157/4885MAP2K4 45/4885MAPK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.